Ataxia telangiectasia (AT) is an autosomal recessive disease characterized by neurological and immunological symptoms, radiosensitivity and cancer predisposition. The gene mutated in AT, designated the ATM gene, encodes a large protein kinase with a PI-3 kinase-related domain. In this study, we investigated the mutational spectrum of the ATM gene in a cohort of AT patients living in Germany. We amplified and sequenced all 66 exons and the flanking untranslated regions from genomic DNA of 66 unrelated AT patients. We identified 46 different ATM mutations and 26 sequence polymorphisms and variants scattered throughout the gene. A total of 34 mutations have not been described in other populations. Seven mutations occurred in more than one family, but none of these accounted for more than five alleles in our patient group. The majority of the mutations were truncating, confirming that the absence of fulllength ATM protein is the most common molecular basis of AT. Transcript analyses demonstrated single exon skipping as the consequence of most splice site substitutions, but a more complex pattern was observed for two mutations. Immunoblot studies of cell lines carrying ATM missense substitutions or in-frame deletions detected residual ATM protein in four cases. One of these mutations, a valine deletion proximal to the kinase domain, resulted in ATM protein levels >20% of normal in an AT lymphoblastoid cell line. In summary, our results survey and characterize a plethora of variations in the ATM gene identified by exon scanning sequencing and indicate a high diversity of mutations giving rise to AT in a non-isolated population.
INTRODUCTION
Ataxia telangiectasia (AT) is an autosomal recessive disorder that affects ∼1:40 000-1:300 000 children in various ethnic groups (1) (2) (3) (4) . AT is a pleiotropic disease characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, thymus dysplasia, immunodeficiency and bronchopulmonary infections, gonadal dysgenesis, chromosomal instability, abnormal X-ray sensitivity and cancer predisposition (1, 2) . Cultured cells from AT patients are also hypersensitive to ionizing radiation and show defective activation of radiation-induced cell cycle checkpoints, including retarded p53 stabilization (3) (4) (5) (6) (7) (8) . Heterozygous carriers of an AT mutation are clinically unaffected, but there is reported evidence from epidemiological studies that AT heterozygosity predisposes to some epithelial cancers, in particular breast cancer (9) (10) (11) (12) (13) . The gene mutated in AT, ATM, has been localized to chromosome 11q23 (14) and subsequently was isolated and characterized (15, 16) . It spans ∼150 kb of genomic sequence and contains 66 exons (17, 18) . The ATM gene gives rise to a ubiquitously expressed transcript of ∼13 kb which encodes a nuclear 350 kDa protein with homology to PI-3 kinases and related proteins involved in DNA damage responses and cell cycle regulation (16, (19) (20) (21) (22) . While the precise function of the ATM gene is still unknown, the ATM gene product is yet believed to sense DNA double-strand breaks (7) and to regulate physiological responses via p53-or Chk1-mediated pathways (4, 23) . Furthermore, the non-receptor tyrosine kinase c-Abl has been identified as a downstream target of the ATM protein (4, 24, 25) . Numerous different mutations in the ATM gene have been identified in classical AT and in some patients with variant forms of AT (26) . The majority of the published mutations in the ATM gene are truncating, although missense substitutions and in-framedeletions have also been found (15, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Until now most studies have used cDNA-based screening techniques for mutation analysis and, thus, a number of the reported exon-skipping mutations have remained uncharacterized at the genomic level (26) . Now that the exon-intron structure of the ATM gene has been fully elucidated (17) and complete sequence information is available for the entire ATM gene (18) , mutation scanning methods using genomic DNA have become feasible. In the present study, we established primers and PCR conditions to amplify all exons and exon-flanking intron regions of the ATM gene. We applied automated sequencing of the PCR products to mutation scanning. As a result, we report the spectrum of ATM gene mutations identified in 66 AT families diagnosed in Germany.
RESULTS
We designed a set of 68 PCR primer pairs based on the published genomic sequence information to amplify all 66 exons and the adjacent intron regions of the ATM gene. The primers were arranged in a fashion to allow for amplification of most exons under the same conditions. Due to its large size of 3.8 kb, the last exon 66 was amplified in nine overlapping fragments. In a few other instances, two exons were amplified jointly together with a small intervening sequence. All primers and PCR conditions are compiled in Materials and Methods. Sequence alterations and their allele frequencies are listed here as polymorphisms or neutral variants if the variations were found in similar frequencies on control chromosomes or if there was no obvious evidence for a potential disease-causing effect from the nature and location of a rare variation. Some of the variants have previously been described by Vorechovsky et al. (31, 62) . Restriction enzymes to distinguish between variant alleles are as indicated with (+) designating the creation and (-) the abolition of a recognition site.
A cohort of 66 German AT patients were investigated for their mutations in the ATM gene. From genomic DNA samples of all patients, PCR products were obtained for all exons and exon-flanking intron regions and were sequenced on both strands. We obtained ∼25 kb of edited sequence information from each patient ( Fig. 1 ; see also Materials and Methods). A total of 46 different mutations were identified on 75 of the 132 alleles, corresponding to a 57% detection rate. In addition, 26 variants and polymorphisms of unknown biological significance were found. The sequence alterations suggesting pathological consequences (mutations) are compiled in Table 1 and the sequence variants that are likely to represent polymorphisms or neutral variations are compiled in Table 2 . The distribution of mutations throughout the ATM gene is illustrated in Figure 2 . Each of the mutations was confirmed by an independent screening method in the parental DNA samples whenever available.
A major fraction of 27 different mutations (57%) were nonsense mutations or small frameshift insertions/deletions leading to a premature translation termination codon. This subset of the mutations included 14 frameshift deletions and seven insertions comprising between 1 and 11 nt, as well as one more complex frameshift mutation that had emerged from the deletion of a single guanine and the insertion of a 21 nt quasi-palindromic sequence ( Table 1 ). The truncating mutations were scattered throughout the entire ATM gene without apparent clustering. Our data did not allow us to determine whether differences in the AT phenotype in our patients may result from different locations of the premature termination codon within the ATM gene. At any rate, three termination mutations were located downstream of the deduced kinase domain, indicating that even premature stop codons in the very final part of the protein impair ATM expression, stability or function to a disease-causing degree.
Nine different mutations were identified within splice sites of the ATM gene. Mutations within the conserved AG and GU dinucleotides of the acceptor and donor splice sites were regarded as pathogenic, since this mutation type results in aberrant splicing by exon skipping or activation of cryptic splice sites (42) . Both effects were observed to occur together in lymphoblasts from patients with the common mutation 7630-2A→C (Table 3) . Another mutation, 2921+3A→T, only affected the poorly conserved position +3 in the donor splice site of intron 21, but nevertheless caused a complex aberrant splicing pattern in ATM mRNA, in which exon 21 alone or both exons 20 and 21 were deleted (Table 3) . Three other mutations, 2250G→A, 3576G→A and R2032K substituted the final nucleotide of exons 16, 26 and 43, respectively. All of them were confirmed to represent true splicing mutations since skipping of the affected exon was observed in transcripts from patient lymphoblastoid cell lines or fibroblasts (Table 3) . No alternative splicing of these exons was detected in lymphocytes from control persons (43; M. Nicke, personal communication). The families of the three patients with the splicing mutation 3576G→A were of Italian, Turkish and Georgian descent, respectively, suggesting that this splicing mutation may be more common in south or south east Europe than in Germany itself. Finally, a deletion of 5 bp, 6096-9del5, within the polypyrimidine tract of intron 43 was found to be associated with skipping of the downstream exon in fibroblasts of the heteroallelic patient. Since this deletion retains only four pyrimidines immediately preceding exon 44, it apparently impedes splice site recognition and thereby acts as a splicing mutation similar to previously reported polypyrimidine sequence alterations in in vitro reactions and in other genetic diseases (44, 45) .
Missense substitutions constituted ∼20% of the identified mutations. Two missense mutations, R2849P and G2867R, reside within the kinase domain and affect residues that are highly conserved among ATM-homologous proteins from different species (16) . No mutations were found within the putative leucine zipper region encoded by exon 27 (16) or within the proposed c-Abl binding site encoded by exon 30 (25) . Most missense mutations resulted in the substitution of a conserved amino acid identical in the human and murine ATM proteins, the exception being R785C (46) . We screened ∼100 control chromosomes from anonymous donors for the presence of missense substitutions identified in the AT patients, in order to exclude the possibility that such amino acid mutations represent common polymorphisms. Five missense substitutions (S49C, F858L, P1054R, D1853V and D1853N) were classified as probable polymorphisms after this analysis, since they were also found in our analysis of control chromosomes (P1054R, D1853V and D1853N) or have been previously reported in DNA samples from random blood donors [e.g. by Vorechovsky et al. (31, 62) ]. Although P1054R was significantly more frequent in our AT patient group (10/132 chromosomes) than in random donors (4/100 chromosomes), this difference appeared to be due to the association of the relatively common AT splicing mutation 3576G→A with the P1054R substitution on the same allele in our AT patients and, thus, to a linkage disequilibrium. With regard to the remaining missense substitutions listed in Table 1 , it must cautiously be noted that the absence of an amino acid substitution in a limited number of controls does not fully prove its causative role in the pathogenesis of AT disease. In order to further characterize the effect of non-truncating mutations, we analysed cell lines Table 1 , L-87 is heterozygous for mutation 2250G→A and corresponds to sample Ac053 in Table 1 and L-105 is from a patient whose mutations remained unknown after sequencing all ATM exons and adjacent intron regions).
carrying ATM missense substitutions or in-frame deletions by immunoblot analysis for their levels of ATM protein expression ( Fig. 3 and Table 4 ). A minority of these mutant cell lines revealed detectable but very low amounts of ATM protein. Only the cell line homozygous for the V2662del mutation exhibited higher ATM levels, which varied from culture to culture: This mutant exhibits levels which range between apparently normal and 20% of the normal level. A typical example is shown in Figure 3 (designated L106), which in this case showed a level of ∼41%. This protein is probably not very stable and therefore fluctuates according to physiological conditions. It may be possible, but could not be determined, that it is very unstable in certain tissues. The underlying mutation which deletes one of three consecutive valines in exon 56 was identified in a single homozygous German AT patient. The 7-year-old girl developed ataxia by the age of 3 years. She has remained free of recurrent infections so far, despite laboratory evidence of absent IgA and lowered IgG3 levels. Chromosomal instability was shown by increased bleomycininduced chromosome breakage rates. Hence, clinical and cytogenetic examinations of this patient reveal features of classic AT and further functional analysis of the mutant ATM protein is in progress to yield insight into the molecular pathogenesis of the disease. The effect of splicing mutations was characterized by RT-PCR experiments on total RNA isolated from the listed cell types using the primers given in Table 7 . Exon skipping has been observed for all investigated mutations. In addition, one cell line exhibited joint skipping of two neighbouring exons and one exhibited an additional alternatively spliced cDNA species due to the use of a cryptic acceptor splice site. Cell lines with at least one missense mutation or in-frame deletion of the ATM cDNA were analysed for ATM protein levels by immunoblotting. a The designation of lymphoblastoid cell lines refers to the designation of samples shown in Figure 3 .
When we examined the clinical features of other patients carrying missense mutations, some differences in their disease phenotypes became apparent. One patient homozygous for the missense mutation D2016G was found to produce trace amounts of ATM protein and presented with a protracted disease course. He does not manifest telangiectasia or immunodeficiency at his current age of 7 years. Two siblings who were heterozygotes for the missense mutation F570S, combined with an unidentified second mutation, also showed mild manifestations of AT. Both died in their mid-thirties, which is considered unusually long survival. Unfortunately, no cells were available to study ATM protein levels in these cases. In contrast, two patients heteroallelic for the missense mutations R2849P and G2867R, each in combination with a non-identified second mutation, both expired at age 17 after the classical AT disease course. They showed no (R2849P) or low (G2867R) detectable amounts of ATM protein, suggesting that carrying one missense allele affecting the kinase region may not be sufficient to lessen the disease manifestations. Another two patients homozygous for the in-frame splicing mutations 3576G→A and 7630-2A→C, respectively, likewise showed severe AT manifestations and had no detectable ATM protein.
Several intragenic dimorphisms were identified as a by-product in the sequence analysis during the course of this study (Table 2 ), in addition to the known intragenic microsatellite at locus D11S2179 present within the exon 62 PCR product. The allele frequencies of the new dimorphisms are compiled in Table 2 . Of these dimorphisms, nine surpassed the frequency of 0.3 for both alleles and could be used to construct combined haplotypes over the gene. For example, the dimorphisms in introns 7, 17, 62 and 63 and in the 3′-UTR were in strong linkage disequilibrium and defined two major haplotypes, suggesting that intragenic recombination within the ATM gene is a rare event. No efforts were made in this study to analyse the allele frequencies of these dimorphisms in the general population, since a previous analysis of another linked marker in intron 48 had not revealed any significant differences between the alleles of healthy, breast cancer or AT individuals in the German population (48) . Some of the dimorphisms described in our study can be assayed as natural RFLPs (Table 2) , which may be useful for indirect genetic diagnosis within AT families or to study loss of heterozygosity in malignancies.
At the end of our sequencing efforts, we were able to identify 46 different ATM mutations on 75 of 132 AT alleles. None of the detected mutations accounted for more than five alleles, and only seven mutations, namely 822delT, 2250G→A, 3576G→A, 3801delG, 4909+1G→A, R2443X and 7630-2A→C, occurred in more than one apparently unrelated AT family. Some of the identified mutations are also present in other populations. There are 12 mutations in our panel whose independent detection has been reported by other investigators: 822delT, 1561delAG, 2250G→A, 2502insA, 3085insA, 3576G→A, 3801delG, E1978X, R2032K, R2443X, 7630-2A→C and 8814del11 (29, 35, 36) . In contrast, the high incidence of new and individual AT mutations in our cohort of patients demonstrates marked mutational heterogeneity of AT in Germany. Finally, it is notable that the complete AT genotype could only be determined in 24 of our patients (17 homozygotes and seven compound heterozygotes), whereas one of both mutations was uncovered in 26 patients and no ATM mutation was found in 16 patients. Thus, further molecular analyses apart from our automated sequencing approach are required to determine the molecular basis of AT disease in the patient group where the complete ATM genotype could not yet be defined.
DISCUSSION
Although numerous mutations have been previously identified in AT families, the present study is the first which systematically examines the whole coding region and all flanking intron portions of the ATM gene by high throughput automated sequencing of PCR products from genomic DNA in a large cohort of AT patients. This approach provides insight into the mutational heterogeneity of AT in Germany and into the polymorphic variability of the ATM gene. Some previous studies reported either a high frequency of distinct AT mutations or uncovered singular mutations that were common in isolated populations due to founder effects (15, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) 49, 59, 60) . In our cohort, direct sequencing identified 46 different mutations of the ATM gene in 50 of 66 AT patients. These mutations were well distributed over the whole gene, which appears in contrast to hitherto published studies, where mutations were more frequent in the 3′-region of the gene (26) . However, the over-representation of C-terminal ATM gene mutations may be explained by more intense screening for mutations in the initially published 3′-part of the gene (26) . None of the mutations in our cohort occurred in more than four families and only 12 of the 46 mutations have been independently published for other populations (29, 32, (34) (35) (36) . Hence, common mutations exist in AT, but they seem to be present at only low frequencies in Caucasians. It will be interesting to determine by haplotype comparison whether such mutations have a common origin or whether they represent recurrent mutational events. Those mutations which in our study were present in more than one family shared the same intragenic marker haplotype, as exemplified by the association of the 3576G→A splicing mutation with the missense variant P1054R on the same allele in three families with different population backgrounds. This mutation has also been identified by other investigators in Italian AT patients (35) . Furthermore, heterozygosity for the P1054R allele has recently been implicated in the aetiogenesis of breast cancer (61) , suggesting that either the amino acid substitution P1054R could have a modifying effect on ATM function or that the associated 3576G→A mutation may predispose to malignancy. The mutations 2250G→A and 3801delG have previously been reported in AT families from the British Isles, suggesting an origin in common with the German AT patients in our study (36) . Similarly, the mutations 3085insA, R2032K and 7630-2A→C have recently been identified in Polish patients and may share the same origin with the German families reported here (35) . In contrast, the previously reported occurrence of mutation R2443X in African-Americans (35) may reflect an independent mutational event as the underlying nucleotide substitution affects a CpG dinucleotide, known hot spots of mutations in general (50) .
More than half of the identified AT mutations were nonsense mutations or small frameshift deletions or insertions. Including splicing mutations, four out of five AT mutations are predicted to severely truncate the ATM protein. This finding is an interesting contrast with the mutational spectrum of ATM in T-PLL patients (51, 52) , but it confirms the predominance of null mutations in AT, consistent with what has been reported in other studies (26, 29) . Although there are examples of polymorphic stop codons in other genes, e.g. in BRCA2 (53), truncating mutations would usually be expected to result in the loss of ATM function. This view is corroborated by the observation of significantly reduced amounts or the complete absence of truncated ATM proteins with this type of mutation (20, 54, 55) . The sample of ATM missense mutations in our cohort of AT patients is more difficult to address, because only a few of these affect the highly conserved ATM kinase domain and information about other functional domains of the ATM protein is still limited. Most of the identified amino acid substitutions were not present in a series of control chromosomes, however, their absence in a restricted sample from the general population does not yet prove their physiological significance in causing AT disease. Five amino acid substitutions were classified as probably benign on the basis of their occurrence in the general population, but large case-control studies are required to finally exclude the possibility that these are missense variants predisposing towards disease symptoms. Interestingly, our immunoblot analysis of selected missense mutations and in-frame deletions uncovered one amino acid deletion to be associated with variable ATM protein levels in an AT cell line. In the absence of detailed knowledge about ATM structure and substrates, the identification of such naturally ocurring missense substitutions and deletions can be helpful in elucidating residues of physiological importance and may guide in vitro studies to analyse the processing and function of the ATM protein.
In view of the marked allelic heterogeneity of AT in our patients, no general recommendations concerning screening strategies can presently be deduced from our study. The diversity of many distinct mutations scattered throughout a large gene challenges mutation analysis in AT families and hampers the molecular assessment of AT heterozygosity in other clinical entities, such as breast cancer or leukaemias. In addition, the number of mutations presented here accounts for little more than half of all investigated AT alleles. This detection rate is unexpectedly low given the fact that all exons and adjacent intron regions of the ATM gene were sequenced and carefully evaluated on both strands. Direct sequencing is commonly thought to provide a sensitivity close to 100% in the analysed regions and although some problems with heterozygote detection in automated sequencing are known to impair the identification rate of point mutations, this alone is unlikely to account for missing >40% of the ATM mutations. Another reason would be the ascertainment of patients who have a genetically distinct disease, but genetic heterogeneity also seems unlikely in view of the many heterozygotes in whom ATM gene mutations were identified on one of both alleles. Furthermore, some cell lines from patients with unidentified mutations displayed reduced or absent ATM protein in western blot analyses (as exemplified by sample L105 in Fig. 3) . A more plausible explanation thus would be the assumption of mutations outside the analysed region, e.g. promotor mutations or intronic splicing mutations of the type that have already been observed in variant AT (33) . It is also possible that gross genomic deletions or large inversions account for a substantial portion of AT alleles and have escaped our PCR-based mutation scanning. Similar observations have been made in other inherited diseases, for example familial hypercholesterolemia and haemophilia A (55, 56) . Further studies at the mRNA level and a search for gross deletions and genomic rearrangements must therefore follow to characterize the unidentified AT alleles. Such studies will complement our automated exon scanning sequencing approach and finally result in an optimized strategy for ATM gene mutation analysis at the genomic DNA level in AT families and for heterozygote detection in conditions where ATM involvement is considered.
MATERIALS AND METHODS

Patients
AT patients and their family members were ascertained at one of the participating centres in Wuerzburg, Hannover or Berlin. The diagnosis was established on the basis of typical clinical features, such as ataxia, telangiectasia, elevated α-fetoprotein levels and altered immunoglobulin profiles, and was confirmed by laboratory evidence for X-ray or bleomycin sensitivity, such as cytogenetic analysis of chromosome breakage rates or radio-resistant DNA synthesis (37) or by flow cytometric analysis of cell cycle abnormalities after specific induction (38) . More detailed information on the clinical and laboratory features of patients with particular ATM genotypes can be obtained from the authors upon request. Only apparently unrelated AT patients were included into this study. Four AT patients in our study have been investigated in parallel using cDNA-based mutation screening and the results have been published elsewhere (27) . The genotypes of these patients (designated Aa009, Aa025, Aa027 and Aa028 in Table 1 ) were resolved at the genomic level in the present study and are consistent with the results obtained by Baumer et al. (27) . Little more than half of our 66 AT patients were of German descent, whereas the others originated from Turkey, Italy, Denmark, Switzerland, the Czech Republic, Romania, Georgia or Lithuania. After informed consent had been obtained, blood samples were collected from the AT patients and, wherever available, their parents. Genomic DNA was extracted from white blood cells according to standard procedures. In some cases, established lymphoblastoid or fibroblast cell lines were used as the source for the extraction of genomic DNA. 1b  s1f2  TCACTCCATCTTTCCTG  1b  s1r2  AGGAGGAGGTTATTGGC  2  s1cf3  AGATAATCTTGACCTGTGGTGAG  6  s6r2  CTCACGCGACAGTAATCTG  8  s8f4  TTCTCTGTGTACTTCAGG  11  s11f2  AATGAAGATACCAGATCC  11  s11r2  GGTAGACAAATGACTTAGTTCTG  12  s12f2  TTTTAGGCTACAGATTGC  12  s12r2  GTAAGTCAGACATAATGC  17  s17f4  TCCAAGATCAAAGTACAC  17  s17r1  ATGAGTTGTGACAATCCC  19  s19f1  GATTAGGTAAATTTTGACTACAG  20  s20f2  GCTGTTGTGCCCTTCTCTTAGTG  21  s21r1  CTTAACAGAACACATCAG  22  s22f2  ACCACAGCAATGTGTGTTC  26  s26f5  TTAAGTCCCATAGTGCTG  26  s26r5  TGAGGTTCTAATCCATTC  39  s39f1  GAAATTTAATATGTCAACGGG  45  s45r2  CAAGTCAAATTTCTTACCTG  47  s47r4  GCTGCACTTTAGGATAAC  48  s48f2  TCTTGCTTACATGAACTC  49  s49f4  CAGTAGTAAAAGTATTTATTCCC  53  s53f2  AGGCATACACGCTCTAC  53  s53r2  ATGCCTGCATGTGTGAG  58  s58r1  ACTTCACCCAACCAAATG  62  s62r2  CTCCTTTACTTCATATCAC  65 s64r1 CATATACTGAAGATCACAC
Sequence analysis
PCR conditions were established to separately amplify all exons and exon-flanking intron sequences of the ATM gene for every patient sample (Table 5) . PCR amplifications were performed in 50 µl reaction volumes containing 100 ng of genomic DNA, 0.2 mM each dNTP and 2 U Taq DNA polymerase in the reaction buffer supplied by the manufacturer (Boehringer Mannheim). Primer concentrations were 0.5 µM each. As the standard procedure, 35 PCR cycles were performed with 1 min denaturation at 94_C, 1 min annealing at 54 or 59_C, depending on the primer pair, and 1 min elongation at 72_C. The PCR products were purified by PEG precipitation according to a previously published protocol (39) and sequenced on both strands using dye-terminator chemistry (Perkin Elmer). Whenever possible, the PCR primers served as sequencing primers. Because of some background in the sequence trace files or due to poly(A) or poly(T) stretches, 34 sequencing primers had to be chosen anew. These sequencing primers are compiled in Table 6 . Sequence information for all exons was generated and filed using ABI 377 automated sequencers. This data was then assembled using the XGAP program (40) . To facilitate editing, four XGAP sub-projects were generated, each of which consisted of a backbone of reference sequences derived from genomic clones and the data from 18 patients (Fig. 1) . A second round of editing served as an independent confirmation of identified sequence changes.
Transcript analysis
Total RNA was extracted from white blood cells, fibroblasts or lymphoblastoid cell lines by lysis of the cells with guanidinium thiocyanate and extraction of the RNA with acid phenol/chloroform according to the protocol of Chomczynski and Sacchi (41) . An aliquot of 1 µg of total RNA was reverse transcribed using a First Strand cDNA Synthesis Kit (Pharmacia) with random hexamers as primers. One-fifth of the cDNA was used as the template in the subsequent PCR amplification of a cDNA region spanning several exons and containing the mutation of interest. The primers used for RT-PCR are compiled in Table 7 . Splicing products were analysed after 32 cycles of PCR by electrophoresis in NuSieve agarose, excised and eluted from the gel and sequenced. For quantitative determination of the relative frequencies of the splicing products, the PCR products were radioactively labelled and separated on a 6% denaturing polyacrylamide gel. The incorporated radioactivity was then quantitated by phosphorimager analysis (Fuji).
Western blotting
Protein extraction and immunoblotting analysis were performed as described by Ziv et al. 
